Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To characterize the mechanisms of the 4G/5G-dependent PAI-1 expression in mast cells (MCs), a major source of PAI-1 and key effector cells in asthma.
|
18234320 |
2008 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results indicate that PAI-1 is strongly involved in the pathogenesis of asthma, and intra-airway administration of PAI-1-siRNA may be able to become a new therapeutic approach for asthma.
|
21926267 |
2011 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the independent and joint effects of a PAI-1 gain of function polymorphism and bronchiolitis / Respiratory Syncytial Virus (RSV) or other lower respiratory infections (LRI) within the first 2 years of life on asthma risk, asthma exacerbations and lung function.
|
27556405 |
2016 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We studied associations between a functional SERPINE1 -675 4G/5G promoter polymorphism and asthma development, severity and response to ICSs.
|
21478212 |
2011 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To assess the ability of asthmatic airway epithelial cells (AECs) to repair mechanically induced wounds and to investigate the role that plasminogen activator inhibitor-1 plays in the repair process.
|
19037965 |
2008 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We estimated the relationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status.
|
28543872 |
2017 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
It has been established that PAI-1 4G allele may be a genetic risk factor for childhood asthma but ACE gene I/D polymorphisms do not play a role in the development of asthma in the sample of Turkish children.
|
22361338 |
2015 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that PAI-1 could play an important role in airway remodeling of asthma, and inhibition of PAI-1 activity could represent a novel therapeutic approach in the management of airway remodeling.
|
10975829 |
2000 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Both the C allele of CD14 and the 4G allele of SERPINE1 were more frequently encountered in HDM-allergic asthmatic patients than in healthy control individuals.
|
18714537 |
2008 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that Turkish children with asthma or allergic rhinitis have a higher prevalence of PAI-1 4G allele compared with their healthy peers.
|
19063817 |
2009 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In a mouse ovalbumin (OVA) asthma model, we increased plasminogen activator activity in the lung by administering exogenous uPA or by using mice genetically deficient in the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) to assess the role of this system in asthma pathogenesis.
|
19098125 |
2009 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
DNA taken from subjects with clinically manifested asthma and other allergic diseases (n = 207) and from reference ethnically age-gender-matched unrelated subjects (n = 186) was examined for base deletions/insertions in the PAI-1 gene.
|
11972486 |
2002 |
Asthma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Vitamin D has also been implicated in asthma through its effects on the obesity, bacillus Calmettee Guérin (BCG) vaccination and high vitamin D level, vitamin D supplement, checkpoint protein kinase 1 (Chk1), plasminogen activator inhibitor-1 (PAI-1) and gamma delta T cells (gdT).
|
22532985 |
2012 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that PAI-1 may promote the development of asthma by regulating airway remodelling, airway hyperresponsiveness (AHR), and allergic inflammation.
|
19438580 |
2009 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The present findings suggest a synergistic interaction between FCER1B and PAI-1 genes in asthma susceptibility.
|
16839401 |
2006 |
Asthma
|
0.300 |
Biomarker
|
disease |
RGD |
Tissue plasminogen activator activity was significantly decreased in asthmatic animals (4.48 +/- 0.4 vs. 6.7 +/- 0.3 ng/ml for OVA/OVA and OVA/VEH; p < 0.05), and PAI-1 activity was statistically significantly higher in asthma rats (0.8 +/- 0.05 vs. 0.5 +/- 0.03 ng/ml for OVA/OVA vs. OVA/VEH; p < 0.05). alpha2-Antiplasmin was higher in rats receiving OVA sensitization than in those that were sham sensitized (p < 0.05).
|
18594148 |
2008 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A PAI-1 functional polymorphism (rs1799768, 4G5G) was characterized in subjects with poorly controlled asthma enrolled in a randomized clinical trial of soy isoflavones (n = 265).
|
30707970 |
2019 |
Asthma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In summary, PAI-1 may play an important role in the pathogenesis of asthma and further studies evaluating the mechanisms of PAI-1 action may lead to the development of a novel therapeutic target for the treatment and prevention of asthma.
|
14734792 |
2004 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggested that the -675 4G/5G polymorphism of PAI-1 gene was a risk factor of asthma.
|
22479620 |
2012 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The objective is to investigate the frequency of PAI-1 gene polymorphism (4G/5G) in patients with a lung ventilation dysfunction in asthma and allergic rhinitis.
|
28258374 |
2017 |
Asthma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The -675 4G/5G plasminogen activator inhibitor-1 (PAI-1) polymorphism is linked with asthma and bronchial hyperreactivity.
|
17579282 |
2007 |
Asthma
|
0.300 |
Biomarker
|
disease |
LHGDN |
Studies with transgenic mice have revealed a functional role for PAI-1 in wound healing, atherosclerosis, metabolic disturbances such as obesity and insulin resistance, tumor angiogenesis, chronic stress, bone remodeling, asthma, rheumatoid arthritis, fibrosis, glomerulonephritis and sepsis.
|
15634264 |
2005 |
Asthma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These novel findings suggest that asthma itself is associated with decreased CRR and reduced fibrinolytic potential resulting from alterations in clot architecture and elevated levels of plasma FXIII and PAI-1.
|
27659252 |
2017 |